Form 4: Hims & Hers CMO Carroll Granted 150,489 RSUs

Hims & Hers Health, Inc. Director and Chief Medical Officer Patrick Harrison Carroll was granted 150,489 Restricted Stock Units, vesting over four years.

Summary

• Patrick Harrison Carroll, Director and Chief Medical Officer of Hims & Hers Health, Inc. (HIMS), was granted 150,489 Restricted Stock Units (RSUs).
• The transaction date for this grant was March 11, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs are subject to a service-based vesting requirement over a 4-year period.
• Vesting will occur in substantially equal quarterly installments on March 15, June 15, September 15, and December 15, with the first vesting date on June 15, 2026.
• Following this transaction, Patrick Harrison Carroll beneficially owns 150,489 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at aligning management incentives with shareholder value and ensuring key talent retention.

Positives

• The grant of Restricted Stock Units aligns the Chief Medical Officer's long-term interests with those of the shareholders.
• Equity compensation serves as a key retention tool for executive talent within the company.

Negatives

• The grant of RSUs represents potential future dilution for existing shareholders as the units vest and convert into Class A Common Stock.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) to key executives like the Chief Medical Officer is a standard practice across various industries, particularly in high-growth sectors like telehealth. This form of compensation is widely used to incentivize long-term performance and ensure executive retention by aligning their financial success with the company's stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice, comparable to compensation structures observed at peer companies in the healthcare technology and direct-to-consumer health sectors such as Teladoc Health (TDOC) and GoodRx (GDRX).
• A four-year service-based vesting schedule is typical for RSU grants, providing a standard long-term incentive and retention mechanism consistent with global benchmarks for executive equity compensation.

Stakeholder Impact

• Shareholders: Potential for future dilution as RSUs vest, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees: Reinforces the company's commitment to equity-based compensation, potentially boosting morale and retention among other employees.

Next Steps

• The RSUs will vest in substantially equal quarterly installments over a four-year period, commencing on June 15, 2026.

Key Dates

Recommendation

This Form 4 filing details a standard RSU grant to a key executive, which is a routine compensation event. It does not present new information that would materially alter the company's fundamental outlook or warrant a change in investment recommendation. The grant aligns executive interests with shareholders but does not indicate any immediate catalysts for significant share price movement.

Keywords

Hims & Hers Health, HIMS, Restricted Stock Units, RSU, Insider Transaction, Form 4, Patrick Carroll, Chief Medical Officer, Director, Equity Grant, Executive Compensation